File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chinese medicines as a resource for liver fibrosis treatment

TitleChinese medicines as a resource for liver fibrosis treatment
Authors
Issue Date2009
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.cmjournal.org/home
Citation
Chinese Medicine, 2009, v. 4, article no. 16 How to Cite?
AbstractLiver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.© 2009 Feng et al; licensee BioMed Central Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/89655
ISSN
2021 Impact Factor: 4.546
2020 SCImago Journal Rankings: 0.972
PubMed Central ID
References

 

DC FieldValueLanguage
dc.contributor.authorFeng, Yen_HK
dc.contributor.authorCheung, KFen_HK
dc.contributor.authorWang, Nen_HK
dc.contributor.authorLiu, Pen_HK
dc.contributor.authorNagamatsu, Ten_HK
dc.contributor.authorTong, Yen_HK
dc.date.accessioned2010-09-06T09:59:58Z-
dc.date.available2010-09-06T09:59:58Z-
dc.date.issued2009en_HK
dc.identifier.citationChinese Medicine, 2009, v. 4, article no. 16en_HK
dc.identifier.issn1749-8546en_HK
dc.identifier.urihttp://hdl.handle.net/10722/89655-
dc.description.abstractLiver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.© 2009 Feng et al; licensee BioMed Central Ltd.en_HK
dc.languageengen_HK
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.cmjournal.org/homeen_HK
dc.relation.ispartofChinese Medicineen_HK
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleChinese medicines as a resource for liver fibrosis treatmenten_HK
dc.typeArticleen_HK
dc.identifier.emailFeng, Y: yfeng@hku.hken_HK
dc.identifier.emailTong, Y: tongyao@hku.hken_HK
dc.identifier.authorityFeng, Y=rp00466en_HK
dc.identifier.authorityTong, Y=rp00509en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1749-8546-4-16en_HK
dc.identifier.pmid19695098-
dc.identifier.pmcidPMC3224967-
dc.identifier.scopuseid_2-s2.0-77955773072en_HK
dc.identifier.hkuros166268en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955773072&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume4en_HK
dc.identifier.spagearticle no. 16-
dc.identifier.epagearticle no. 16-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridFeng, Y=24467969600en_HK
dc.identifier.scopusauthoridCheung, KF=8763216400en_HK
dc.identifier.scopusauthoridWang, N=35072317700en_HK
dc.identifier.scopusauthoridLiu, P=36065603800en_HK
dc.identifier.scopusauthoridNagamatsu, T=7006510058en_HK
dc.identifier.scopusauthoridTong, Y=9045384000en_HK
dc.identifier.citeulike5490239-
dc.identifier.issnl1749-8546-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats